Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 17/20 | 1.00 |
| ▸ | MAP4K2 | Q12851 | 17/20 | 1.00 |
| ▸ | MAPK3 | P27361 | 1/20 | 1.00 |
| ▸ | BMX | P51813 | 4/20 | 0.81 |
| ▸ | ABL1 | P00519 | 3/20 | 0.81 |
| ▸ | BCR | P11274 | 1/20 | 0.81 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.81 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.81 |
| ▸ | BTK | Q06187 | 1/20 | 0.77 |
| ▸ | LCK | P06239 | 1/20 | 0.75 |
| ▸ | FES | P07332 | 1/20 | 0.75 |
| ▸ | RET | P07949 | 1/20 | 0.75 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.75 |
| ▸ | KIT | P10721 | 1/20 | 0.75 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.75 |
| ▸ | SRC | P12931 | 1/20 | 0.75 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.75 |
| ▸ | FLT1 | P17948 | 1/20 | 0.75 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.75 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29468185 | 1.00 | TNK2 (1.00) | TNK2MAP4K2MAPK3BMXABL1 | |
| SCHEMBL1521896 | 0.92 | TNK2 (0.84) | TNK2MAP4K2MAPK3BMXABL1 | |
| SCHEMBL5546714 | 0.92 | TNK2 (0.84) | TNK2MAP4K2MAPK3BMXABL1 | |
| SCHEMBL3139566 | 0.91 | TNK2 (0.84) | TNK2MAP4K2MAPK3BMXABL1 | |
| SCHEMBL3136780 | 0.90 | TNK2 (0.82) | TNK2MAP4K2MAPK3BMXABL1 | |
| SCHEMBL3137360 | 0.90 | TNK2 (0.88) | TNK2MAP4K2MAPK3BMXABL1 | |
| SCHEMBL13521779 | 0.90 | TNK2 (0.93) | TNK2MAP4K2MAPK3BMXABL1 | |
| SCHEMBL29875282 | 0.89 | TNK2 (1.00) | TNK2MAP4K2MAPK3BMXABL1 | |
| SCHEMBL29404264 | 0.89 | TNK2 (1.00) | TNK2MAP4K2MAPK3BMXABL1 | |
| SCHEMBL3135042 | 0.89 | TNK2 (1.00) | TNK2MAP4K2MAPK3BMXABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118355110-A | Method for producing cartilage and bone | 默多克儿童研究所 | 2024-07-16 | — | — | CN | claimed |
| US-20230139800-A1 | CAR T CELL THERAPIES WITH ENHANCED EFFICACY | NOVARTIS AG (CH) | 2023-05-04 | — | — | US | claimed |
| US-20180258149-A1 | CAR T CELL THERAPIES WITH ENHANCED EFFICACY | NOVARTIS AG (CH) | 2018-09-13 | — | — | US | claimed |
| US-20100234400-A1 | COMPOUNDS THAT MAINTAIN PLURIPOTENCY OF EMBRYONIC STEM CELLS | IRM LLC (BM) | 2010-09-16 | — | — | US | claimed |
| US-7371750-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | IRM LLC (BM) | 2008-05-13 | — | — | US | claimed |
| US-20050222177-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-10-06 | — | — | US | claimed |
| EP-4680255-A1 | METHODS FOR PRODUCING STABLE HUMAN CHONDROCTYES AND THEIR USE FOR PROMOTING CARTILLAGE GROWTH AND REPAIR | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250270507-A1 | METHODS FOR PRODUCING CARTILAGE AND BONES | MURDOCH CHILDREN'S RESEARCH INSTITUTE OF THE ROYAL CHILDREN'S HOSPITAL (AU) | 2025-08-28 | — | — | US | disclosed |
| US-20250154467-A1 | CREATION OF VASCULARIZED BIOLOGICAL STRUCTURES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-05-15 | — | — | US | disclosed |
| WO-2024192329-A1 | METHODS FOR PRODUCING STABLE HUMAN CHONDROCTYES AND THEIR USE FOR PROMOTING CARTILLAGE GROWTH AND REPAIR | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-09-19 | — | — | WO | disclosed |
| EP-4416268-A1 | METHODS FOR PRODUCING CARTILAGE AND BONES | Murdoch Children's Research Institute (AU) | 2024-08-21 | — | — | EP | disclosed |
| WO-2024151804-A2 | METHODS AND MATERIALS FOR GENERATING STEM CELL-DERIVED ENDOCRINE CELL TYPES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-07-18 | — | — | WO | disclosed |
| CN-118355110-A | Method for producing cartilage and bone | 默多克儿童研究所 | 2024-07-16 | — | — | CN | disclosed |
| US-20080221098-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-09-11 | — | — | US | disclosed |
| US-20080221098-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-09-11 | — | — | US | disclosed |
| US-20080221098-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-09-11 | — | — | US | disclosed |
| US-7371750-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | IRM LLC (BM) | 2008-05-13 | — | — | US | disclosed |
| US-7371750-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | IRM LLC (BM) | 2008-05-13 | — | — | US | disclosed |
| US-7371750-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | IRM LLC (BM) | 2008-05-13 | — | — | US | disclosed |
| US-20050222177-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139800-A1 | CAR T CELL THERAPIES WITH ENHANCED EFFICACY | TET2, TET1, TET3 | TNK2 2362/4885MAP4K2 4457/4885MAPK3 4278/4885 |
| US-20100234400-A1 | COMPOUNDS THAT MAINTAIN PLURIPOTENCY OF EMBRYONIC STEM CELLS | LIFR, ALPG, BMI1 | TNK2 3577/4885MAP4K2 2176/4885MAPK3 1566/4885 |
| US-20180258149-A1 | CAR T CELL THERAPIES WITH ENHANCED EFFICACY | TET2, TET1, TET3 | TNK2 2362/4885MAP4K2 4457/4885MAPK3 4278/4885 |
| US-20050222177-A1 | Compounds and compositions as protein kinase inhibitors | BMX, FES, FRK | TNK2 203/4885MAP4K2 37/4885MAPK3 136/4885 |
| US-20080221098-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | BMX, FES, FRK | TNK2 203/4885MAP4K2 37/4885MAPK3 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.